Siemens Healthineers (SHL) Status update summary

Q1 2026 financial performance highlights

• Imaging and Precision Therapy revenue grew 6% with strong margins, maintaining a 15% EBIT margin despite tariff and FX headwinds.

• Equipment book-to-bill ratio was 1.12, indicating robust demand.

• Moody's awarded a strong investment grade rating.

• Diagnostics revenue declined 3.1%, with margin at 2.1% due to structural changes in China.

Diagnostics segment challenges and outlook

• Diagnostics faced headwinds from volume-based procurement and reimbursement cuts in China, plus unfavorable sales mix.

• Major distribution and OEM partners in China ordered below expectations, with no catch-up expected.

• Second half expected to improve with OEM volume recovery, core lab growth, and cost reductions from ongoing transformation.

• Nearly 70% of core lab revenues now come from Atellica, with strong instrument deliveries and a major win in Brazil.

• Strategic flexibility for Diagnostics remains intact, with further updates likely this year.

Imaging and Precision Therapy segment performance

• Imaging and Precision Therapy, representing 80% of group revenue, outperformed expectations.

• Imaging saw margin expansion despite 250bps headwinds from tariffs and FX, driven by photon-counting CT and radiopharmaceuticals.

• Radiopharmaceuticals expected to reach $1 billion in revenue, with unique margin structure.

• Precision Therapy grew nearly 6%, with Varian posting 9% growth and strong profitability.